Purdue Institute for Drug Discovery

LMP776 (Indimitecan)

Overview: 

Small molecule inhibitor of topoisomerase I

Status: 

Purdue Faculty: 

Dr. Mark Cushman

Clinical Trial Information: 

Phase 1 Trial - A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas

Development Partner: 

National Institutes of Health

Linus Oncology

Research Articles: 

HPLC method development, validation, and impurity characterization of a potent antitumor indenoisoquinoline, LMP776 (NSC 725776)

Identification, Synthesis, and Biological Evaluation of Metabolites of the Experimental Cancer Treatment Drugs Indotecan (LMP400) and Indimitecan (LMP776) and Investigation of Isomerically Hydroxylated Indenoisoquinoline Analogues as Topoisomerase I Poisons

Synthesis and Biological Evaluation of New Carbohydrate-Substituted Indenoisoquinoline Topoisomerase I Inhibitors and Improved Syntheses of the Experimental Anticancer Agents Indotecan (LMP400) and Indimitecan (LMP776)